Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5520 |
Name | head and neck squamous cell carcinoma |
Definition | A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma head and neck squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA act mut | Gedatolisib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA E545K | Rigosertib Sodium | head and neck squamous cell carcinoma | sensitive | detail... |
TP53 mutant | AZD7762 + Cisplatin | head and neck squamous cell carcinoma | sensitive | detail... |
FGFR1 over exp | Infigratinib | head and neck squamous cell carcinoma | sensitive | detail... |
FBXW7 R505C | Vorinostat | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA mutant | Radiotherapy + Taselisib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA amp | Radiotherapy + Taselisib | head and neck squamous cell carcinoma | sensitive | detail... |
PTEN mutant | Taselisib | head and neck squamous cell carcinoma | resistant | detail... |
FGFR3 over exp | Rogaratinib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS Q61L | Sirolimus + Trametinib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | Sirolimus + Trametinib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | Radiotherapy + Taselisib | head and neck squamous cell carcinoma | sensitive | detail... |
PTEN del | Taselisib | head and neck squamous cell carcinoma | resistant | detail... |
PIK3CA E542K | Apitolisib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA E545K | Apitolisib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA over exp | Gedatolisib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | Gedatolisib | head and neck squamous cell carcinoma | sensitive | detail... |
CHEK1 positive | CCT244747 + Radiotherapy | head and neck squamous cell carcinoma | sensitive | detail... |
CHEK1 positive | CCT244747 + Paclitaxel + Radiotherapy | head and neck squamous cell carcinoma | sensitive | detail... |
FGFR3 D788N | Infigratinib | head and neck squamous cell carcinoma | no benefit | detail... |
FGFR3 S131L | Infigratinib | head and neck squamous cell carcinoma | decreased response | detail... |
FGFR1 positive | Fexagratinib + Vistusertib | head and neck squamous cell carcinoma | sensitive | detail... |
PTEN loss | Rigosertib Sodium | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA amp | AZD8055 | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PTEN loss | AZD8055 | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA amp | Dactolisib | head and neck squamous cell carcinoma | sensitive | detail... |
PTEN loss | Dactolisib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA act mut | AZD8055 + Cetuximab | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
FGFR3 positive | Rogaratinib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA E545K | Carboplatin + Paclitaxel + Temsirolimus | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA mutant | Carboplatin + Paclitaxel + Temsirolimus | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PTEN R130Q | Carboplatin + Paclitaxel + Temsirolimus | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
FGFR2 P253R | Pazopanib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
TP53 mutant | Buparlisib + Paclitaxel | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
FGFR3 D764H | Infigratinib | head and neck squamous cell carcinoma | no benefit | detail... |
PIK3CA wild-type PTEN pos | Cetuximab + Cisplatin | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PTEN positive | Cetuximab | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA H1047R | SHR-A1307 | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA H1047R | Cetuximab | head and neck squamous cell carcinoma | resistant | detail... |
PIK3CA amp | Rigosertib Sodium | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS mutant | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA M1043V | Celecoxib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA E542K | Alpelisib + Cetuximab + Radiotherapy | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA H1047R | Sulindac | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA M1043V | Sulindac | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA R38C | Sulindac | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA E542K PIK3CA F744L | Sulindac | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS over exp | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS over exp | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS over exp | Tipifarnib + Uprosertib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS over exp | Sapanisertib + Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA F977Y | Pictilisib | head and neck squamous cell carcinoma | resistant | detail... |
SMARCB1 inact mut | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
SMARCA4 inact mut | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
PBRM1 inact mut | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
ARID1B inact mut | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
ARID2 inact mut | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
HRAS Q61L | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS G12C | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS A146T | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS G12S | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS G13R | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS K117N | Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
CDKN2A inact mut | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
CDKN2A del | unspecified immune checkpoint inhibitor | head and neck squamous cell carcinoma | not predictive | detail... |
PIK3CA Q75E | Alpelisib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA M1043V | Alpelisib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA N345K | Alpelisib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS G12D | Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS G12V | Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS G12D | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS G12D | SCH772984 + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS Q61L | SCH772984 + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS G12V | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS Q61L | Tipifarnib + Ulixertinib | head and neck squamous cell carcinoma | sensitive | detail... |
HRAS G12D | Tipifarnib + Ulixertinib | head and neck squamous cell carcinoma | sensitive | detail... |
FGFR3 S249C | Erdafitinib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
FGFR2 C382R | Erdafitinib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA H1047R | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA E545K | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA G118D | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047L PIK3CA amp | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA amp | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | STX-478 | head and neck squamous cell carcinoma | sensitive | detail... |
PIK3CA E545K | STX-478 | head and neck squamous cell carcinoma | sensitive | detail... |
CDKN2A negative | Cetuximab + Palbociclib | head and neck squamous cell carcinoma | predicted - sensitive | detail... |
HRAS G12S | Alpelisib + Tipifarnib | head and neck squamous cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00573989 | Phase Ib/II | Erlotinib + Pemetrexed Disodium | Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer | Terminated | USA | 0 |
NCT00588770 | Phase III | Bevacizumab Cisplatin + Docetaxel Cisplatin + Fluorouracil Carboplatin + Docetaxel Carboplatin + Fluorouracil | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 2 |
NCT00660218 | Phase Ib/II | Cetuximab + Paclitaxel | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer | Completed | USA | 0 |
NCT00904345 | Phase II | Cetuximab | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | Terminated | USA | 0 |
NCT00956007 | Phase III | Cetuximab | Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer | Active, not recruiting | USA | CAN | 2 |
NCT00957853 | Phase II | Cetuximab Cixutumumab | Preoperative Treatment With Cetuximab and/or IMC-A12 | Completed | USA | 0 |
NCT01064479 | Phase II | Erlotinib Carboplatin Docetaxel Cisplatin | Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck | Completed | USA | 0 |
NCT01104922 | Phase II | Cetuximab | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT01111058 | Phase II | Everolimus | Everolimus Versus Placebo in Head and Neck Cancer | Terminated | USA | 0 |
NCT01116336 | Phase I | Erlotinib | Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck | Completed | USA | 0 |
NCT01133678 | Phase II | Cetuximab + Cisplatin + Paclitaxel Everolimus | Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck | Terminated | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01316757 | Phase II | Carboplatin + Cetuximab + Erlotinib + Paclitaxel | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | Completed | USA | 0 |
NCT01345669 | Phase III | Afatinib | LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | Terminated | USA | SWE | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT01412229 | Phase II | Carboplatin + Cetuximab + Nab-paclitaxel | Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT01437449 | Phase II | Cetuximab + Cisplatin + Docetaxel Carboplatin | Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Completed | USA | 0 |
NCT01467115 | Phase II | Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab | INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER | Completed | USA | 0 |
NCT01468896 | Phase Ib/II | Cetuximab | Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01488318 | Phase II | Cetuximab + Dasatinib | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT01577173 | Phase II | Cetuximab Duligotuzumab | A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck | Completed | USA | ROU | ITA | HUN | GBR | FRA | ESP | DEU | BGR | BEL | AUS | 0 |
NCT01581970 | Phase II | Cetuximab + Cyclophosphamide | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | Completed | USA | 0 |
NCT01602315 | Phase Ib/II | Alpelisib + Cetuximab | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | NLD | FRA | CAN | AUS | 4 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01612351 | Phase II | Carboplatin + Cisplatin + Lapatinib + Paclitaxel Carboplatin + Lapatinib + Paclitaxel | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | Active, not recruiting | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01711541 | Phase Ib/II | Carboplatin + Etoposide + Veliparib Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Paclitaxel | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | Completed | USA | 0 |
NCT01711658 | Phase II | Cisplatin + Lapatinib + Radiotherapy Cisplatin + Radiotherapy | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. (TRYHARD) | Completed | USA | CAN | 0 |
NCT01716416 | Phase I | Cetuximab + Pazopanib | Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) | Completed | USA | 0 |
NCT01737008 | Phase I | Cisplatin Dacomitinib | Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck | Completed | CAN | 0 |
NCT01744340 | Phase Ib/II | Eribulin Cetuximab | A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | Completed | USA | 0 |
NCT01783587 | Phase I | Afatinib Docetaxel | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | Completed | USA | 0 |
NCT01794845 | Phase II | Cetuximab + Docetaxel | Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma | Terminated | USA | 0 |
NCT01810913 | Phase II | Docetaxel Cisplatin Cetuximab + Docetaxel | Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer | Recruiting | USA | CAN | 1 |
NCT01816984 | Phase Ib/II | Cetuximab Buparlisib | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Completed | USA | 0 |
NCT01824823 | Phase II | Afatinib | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | Terminated | USA | 0 |
NCT01836029 | Phase II | Cisplatin Cetuximab + Fluorouracil Carboplatin | Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT01852292 | Phase II | Buparlisib + Paclitaxel | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | Terminated | USA | POL | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 6 |
NCT01871311 | Phase I | Cetuximab + Nilotinib | A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab | Terminated | USA | 0 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT01935921 | Phase I | Cetuximab + Ipilimumab | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | Completed | USA | 0 |
NCT01946789 | Phase I | Nogapendekin alfa inbakicept | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01979211 | Phase II | Cetuximab | Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT02035527 | Phase Ib/II | Cisplatin + Docetaxel + Sorafenib | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT02057107 | Phase II | Cetuximab Docetaxel | Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Completed | USA | 0 |
NCT02083692 | Phase I | Metformin | Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling | Completed | USA | 0 |
NCT02101034 | Phase Ib/II | Cetuximab + Palbociclib | PD 0332991 and Cetuximab in Patients With Incurable SCCHN | Completed | USA | 0 |
NCT02105636 | Phase III | Methotrexate Cetuximab Docetaxel Nivolumab | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BRA | ARG | 4 |
NCT02110082 | Phase I | Cetuximab + Urelumab | Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | Completed | USA | 0 |
NCT02124707 | Phase II | Carboplatin + Cetuximab + Paclitaxel | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | Completed | USA | 0 |
NCT02124850 | Phase I | Cetuximab | A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337 | Terminated | USA | 0 |
NCT02128906 | Phase II | Cetuximab + Docetaxel Cisplatin | Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC | Recruiting | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | NLD | 0 |
NCT02178072 | Phase II | Azacitidine | Window Trial 5-aza in HNSCC, T-tare | Completed | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02196168 | Phase II | Adavosertib Cisplatin | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Terminated | CAN | 0 |
NCT02205398 | Phase Ib/II | Capmatinib + Cetuximab | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02207530 | Phase II | Durvalumab | Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. | Completed | USA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | 4 |
NCT02241369 | Phase I | INO-3106 + INO-9012 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies | Completed | USA | 0 |
NCT02252042 | Phase III | Pembrolizumab Methotrexate Cetuximab Docetaxel | Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | Completed | 0 | |
NCT02255097 | Phase II | Pembrolizumab | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | Completed | 0 | |
NCT02262741 | Phase I | Tremelimumab Durvalumab | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer | Completed | USA | CAN | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02270814 | Phase II | Carboplatin + Cetuximab + Nab-paclitaxel Cetuximab + Cisplatin + Nab-paclitaxel | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02277184 | Phase I | Cisplatin + Ficlatuzumab | Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT02277197 | Phase I | Cetuximab + Ficlatuzumab | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | Completed | USA | 0 |
NCT02282371 | Phase I | Alpelisib + Cetuximab | Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) | Completed | USA | 0 |
NCT02289209 | Phase II | Pembrolizumab | Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Active, not recruiting | USA | 0 |
NCT02291055 | Phase Ib/II | Durvalumab ADXS11-001 | Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer | Terminated | USA | 0 |
NCT02296684 | Phase II | Pembrolizumab Cisplatin | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02319044 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 4 |
NCT02325401 | Phase I | Cisplatin + Metformin | Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02334319 | Phase I | Ganetespib | Ganetespib Window of Opportunity Study in Head and Neck Cancers | Terminated | USA | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Completed | 0 | |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02369874 | Phase III | Durvalumab + Tremelimumab Durvalumab | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | Completed | USA | ROU | POL | ITA | ISR | HUN | HRV | FRA | ESP | DEU | CZE | BRA | BGR | BEL | AUS | ARG | 8 |
NCT02375958 | Phase I | PCA062 | PCA062 in pCAD-positive Tumors. | Completed | USA | ITA | FRA | ESP | 2 |
NCT02381314 | Phase I | Ipilimumab + MGA271 | Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer | Completed | USA | 0 |
NCT02381535 | Phase I | Cisplatin Onalespib | Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | Active, not recruiting | USA | CAN | 0 |
NCT02383927 | Phase II | Tipifarnib | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | Completed | USA | NLD | ITA | GRC | GBR | FRA | ESP | DEU | BEL | 1 |
NCT02402348 | Phase I | Metformin | Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis | Terminated | USA | 0 |
NCT02415881 | Phase I | Panitumumab | Phase I Panitumumab IRDye800 Optical Imaging Study | Completed | USA | 0 |
NCT02422979 | Phase I | ASP-1929 | Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer | Completed | USA | 0 |
NCT02423863 | Phase II | Poly ICLC | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02449681 | Phase II | TH-4000 | Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS | Terminated | USA | AUS | 0 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02454179 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT02473731 | Phase I | CDX-3379 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Completed | USA | 0 |
NCT02475213 | Phase I | MGA271 + Pembrolizumab | Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer | Completed | USA | 0 |
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |
NCT02499120 | Phase II | Palbociclib Cetuximab | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | Completed | USA | SVK | ROU | POL | ITA | HUN | ESP | CZE | 7 |
NCT02499328 | Phase Ib/II | Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
NCT02508246 | Phase I | Adavosertib Docetaxel Cisplatin | AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02537223 | Phase I | Alpelisib Cisplatin | Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer | Completed | CAN | 0 |
NCT02538510 | Phase Ib/II | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Completed | USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 9 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02555644 | Phase I | Prexasertib Cisplatin Cetuximab | A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer | Completed | USA | FRA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02567422 | Phase I | Berzosertib + Cisplatin | VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02573493 | Phase II | Cisplatin + Nab-paclitaxel Cetuximab + Nab-paclitaxel | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Active, not recruiting | USA | 0 |
NCT02585973 | Phase I | Adavosertib + Cisplatin | Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | Completed | USA | 0 |
NCT02586207 | Phase I | Cisplatin + Pembrolizumab | Pembrolizumab in Combination With CRT for LA-SCCHN | Active, not recruiting | USA | 0 |
NCT02609503 | Phase II | Pembrolizumab | Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin | Completed | USA | 0 |
NCT02626000 | Phase Ib/II | Pembrolizumab + Talimogene laherparepvec | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ITA | GRC | GBR | FRA | ESP | CHE | CAN | BEL | AUT | AUS | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02630420 | Phase I | Cetuximab + Savolitinib | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | Withdrawn | 0 | |
NCT02636036 | Phase I | Enadenotucirev + Pembrolizumab | Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors | Completed | USA | 0 |
NCT02641093 | Phase II | Cisplatin Pembrolizumab | Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02643550 | Phase Ib/II | Cetuximab + Monalizumab | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | FRA | 0 |
NCT02644122 | Phase II | SF1126 | SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes | Terminated | USA | 0 |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02649530 | Phase II | LGK974 | An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma | Withdrawn | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02665416 | Phase I | RO5520985 + Selicrelumab Bevacizumab + Selicrelumab | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors | Completed | USA | NLD | ITA | ESP | DNK | CAN | BEL | 0 |
NCT02684253 | Phase II | Nivolumab | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | Completed | USA | 0 |
NCT02706691 | Phase II | Infigratinib | Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer | Terminated | USA | 0 |
NCT02734537 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Recruiting | USA | 0 |
NCT02741570 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CHE | BRA | AUT | AUS | 4 |
NCT02762513 | Phase II | Axitinib | Expansion Trial for Axitinib In Head And Neck Cancer | Completed | USA | 0 |
NCT02764593 | Phase I | Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab | Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT02769520 | Phase II | Pembrolizumab | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | Active, not recruiting | USA | 0 |
NCT02775812 | Phase I | Cisplatin + Pembrolizumab | Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT02777385 | Phase II | Cisplatin + Pembrolizumab | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | Completed | USA | 0 |
NCT02812524 | Phase I | Ipilimumab | Ipilimumab for Head and Neck Cancer Patients | Active, not recruiting | USA | 0 |
NCT02823574 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | TUR | SWE | ROU | NOR | NLD | ITA | IRL | GBR | FRA | FIN | ESP | CZE | CAN | BRA | BEL | ARG | 4 |
NCT02827838 | Phase I | Durvalumab | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Completed | USA | 0 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | ITA | GBR | ESP | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02892201 | Phase II | Pembrolizumab | Pembrolizumab in HNSCC With Residual Disease After Radiation | Terminated | USA | 0 |
NCT02949700 | Phase Ib/II | Cisplatin + Metformin | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT02952586 | Phase III | Cisplatin Avelumab + Cisplatin | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | Terminated | USA | POL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 6 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT02979977 | Phase II | Afatinib + Cetuximab | Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck | Recruiting | USA | 0 |
NCT02989064 | Phase I | MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Completed | USA | ESP | CAN | 0 | |
NCT02990468 | Phase I | BMX-001 + Cisplatin | A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN) | Completed | USA | 0 |
NCT02994069 | Phase II | Cisplatin | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | Active, not recruiting | USA | 0 |
NCT03019003 | Phase Ib/II | Azacitidine + Durvalumab + Tremelimumab | A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients | Active, not recruiting | USA | 0 |
NCT03022409 | Phase I | Olaparib Ceralasertib | A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | Completed | USA | FRA | 1 |
NCT03049618 | Phase II | Pembrolizumab + sEphB4-HSA | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | Active, not recruiting | USA | 0 |
NCT03057613 | Phase II | Pembrolizumab | A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck | Completed | USA | 0 |
NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
NCT03071757 | Phase I | ABBV-368 ABBV-368 + Nivolumab | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 3 |
NCT03076281 | Phase II | Doxycycline Doxycycline + Metformin Metformin | Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03082534 | Phase II | Cetuximab + Pembrolizumab | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03083873 | Phase II | LN-145 | Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | Completed | USA | 0 |
NCT03085719 | Phase II | Pembrolizumab | Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN | Active, not recruiting | USA | 0 |
NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Active, not recruiting | ITA | GBR | FRA | ESP | BEL | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03098160 | Phase I | Evofosfamide + Ipilimumab | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | Unknown status | USA | 0 |
NCT03109158 | Phase Ib/II | Cetuximab + Fluorouracil + NC-6004 | NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ROU | HUN | BGR | 0 |
NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | ESP | BEL | AUS | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03138070 | Phase I | Alpelisib | A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 | Active, not recruiting | CAN | 0 |
NCT03153982 | Phase II | Ruxolitinib | Ruxolitinib in Operable Head and Neck Cancer | Terminated | USA | 0 |
NCT03162224 | Phase Ib/II | Durvalumab + MEDI0457 | Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer | Completed | USA | 0 |
NCT03162731 | Phase I | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer | Completed | USA | 0 |
NCT03174275 | Phase II | Carboplatin + Cisplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Paclitaxel | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03194373 | Phase II | Carboplatin + Palbociclib | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03212469 | Phase Ib/II | Durvalumab + Tremelimumab | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) | Active, not recruiting | FRA | 0 |
NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Completed | USA | ISR | AUS | 0 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03238638 | Phase II | Epacadostat + Pembrolizumab | A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy | Withdrawn | USA | 0 |
NCT03245489 | Phase I | Pembrolizumab | Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
NCT03246685 | Phase II | Pembrolizumab + PGG beta-glucan | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | Terminated | USA | 0 |
NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Completed | USA | DEU | 0 |
NCT03247712 | Phase Ib/II | Nivolumab | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | Active, not recruiting | USA | 0 |
NCT03254927 | Phase II | CDX-3379 + Cetuximab | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT03258554 | Phase II | Cetuximab Durvalumab | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin | Active, not recruiting | USA | CAN | 0 |
NCT03264066 | Phase II | Atezolizumab + Cabozantinib | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | Completed | USA | HUN | GBR | DEU | BEL | 1 |
NCT03265080 | Phase I | ADXS-NEO | Expressing Personalized Tumor Antigens Study | Terminated | USA | 0 |
NCT03283605 | Phase Ib/II | Durvalumab + Tremelimumab | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | Active, not recruiting | CAN | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03301896 | Phase I | LHC165 + Spartalizumab LHC165 | Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | ITA | ESP | DEU | BEL | 2 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Active, not recruiting | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03325465 | Phase II | Epacadostat + Pembrolizumab | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | Withdrawn | USA | 0 |
NCT03336606 | Phase I | Tavolimab | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | Active, not recruiting | USA | 0 |
NCT03341936 | Phase II | Lirilumab + Nivolumab | Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting | USA | 0 |
NCT03342352 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | Withdrawn | 0 | |
NCT03342911 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
NCT03343613 | Phase I | LY3300054 + LY3381916 LY3381916 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Terminated | USA | ITA | FRA | ESP | DNK | BEL | 0 |
NCT03349710 | Phase III | Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Completed | USA | TUR | POL | ITA | FRA | ESP | 4 |
NCT03356223 | Phase II | Abemaciclib | Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) | Completed | FRA | 0 |
NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Active, not recruiting | CAN | 0 |
NCT03358472 | Phase III | Pembrolizumab Carboplatin + Fluorouracil Epacadostat + Pembrolizumab Cetuximab + Cisplatin | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | Active, not recruiting | USA | TUR | POL | ITA | HUN | GBR | ESP | CAN | AUT | AUS | 4 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03370276 | Phase Ib/II | Cetuximab + Nivolumab | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03381183 | Phase Ib/II | Cyclophosphamide + Durvalumab + Tremelimumab | IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03386838 | Phase III | Linrodostat + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil | An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck | Withdrawn | USA | 0 |
NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Terminated | USA | 0 |
NCT03406247 | Phase II | Ipilimumab + Nivolumab Nivolumab | Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) | Recruiting | FRA | 0 |
NCT03409458 | Phase Ib/II | Avelumab + Imifoplatin | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) | Completed | USA | CHE | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03418480 | Phase Ib/II | BNT113 | HPV Anti-CD40 RNA Vaccine (HARE-40) | Completed | GBR | 0 |
NCT03422536 | Phase II | Ficlatuzumab Cetuximab + Ficlatuzumab | Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03447314 | Phase I | GSK1795091 + GSK3174998 GSK3174998 | Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ESP | CAN | 0 |
NCT03452137 | Phase III | Atezolizumab | A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Terminated | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 10 |
NCT03463161 | Phase II | Epacadostat + Pembrolizumab | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (ORKA) | Terminated | USA | 0 |
NCT03468218 | Phase II | Cabozantinib + Pembrolizumab | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy | Active, not recruiting | USA | 0 |
NCT03474497 | Phase Ib/II | Aldesleukin + Pembrolizumab + Radiotherapy | Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | Recruiting | USA | 0 |
NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT03498378 | Phase I | Avelumab + Cetuximab + Palbociclib | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03509012 | Phase I | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) | Active, not recruiting | USA | ESP | 3 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03518606 | Phase Ib/II | Durvalumab + Tremelimumab + Vinorelbine | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) | Active, not recruiting | FRA | 0 |
NCT03521570 | Phase II | Nivolumab | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | Completed | USA | 0 |
NCT03522584 | Phase Ib/II | Durvalumab + Tremelimumab | Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT03524326 | Phase I | Cetuximab + Lenvatinib | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03529422 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | Active, not recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
NCT03544723 | Phase II | Nivolumab Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Ad-p53 in Head and Neck Cancer | Unknown status | USA | 0 |
NCT03546582 | Phase II | Pembrolizumab | SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE) | Recruiting | USA | CAN | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03565783 | Phase II | Cemiplimab | Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
NCT03576417 | Phase III | Cisplatin Cisplatin + Nivolumab | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) | Active, not recruiting | FRA | 0 |
NCT03589339 | Phase I | NBTXR3 NBTXR3 + unspecified PD-1 antibody | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | Recruiting | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03618654 | Phase I | Durvalumab + Metformin Durvalumab | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03624231 | Phase II | Durvalumab Durvalumab + Tremelimumab | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) | Completed | DEU | 0 |
NCT03625323 | Phase II | Eftilagimod alpha + Pembrolizumab | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) | Active, not recruiting | USA | GBR | ESP | AUS | 1 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Completed | USA | 0 |
NCT03635164 | Phase I | Durvalumab | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03637764 | Phase Ib/II | Atezolizumab + Isatuximab Isatuximab | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | ESP | CZE | CAN | BEL | 1 |
NCT03645928 | Phase II | Lifileucel + Pembrolizumab LN-145 LN-145 + Pembrolizumab | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Recruiting | USA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | 0 |
NCT03646461 | Phase II | Ibrutinib + Nivolumab Cetuximab + Ibrutinib | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
NCT03650764 | Phase Ib/II | Pembrolizumab + Ramucirumab | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03652233 | Phase I | Afatinib + Nivolumab | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Withdrawn | 0 | |
NCT03655444 | Phase Ib/II | Abemaciclib + Nivolumab | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | Terminated | USA | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Completed | USA | 0 |
NCT03667482 | Phase I | Cabozantinib + Cetuximab | Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer | Completed | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03690986 | Phase I | Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | Recruiting | USA | 0 |
NCT03691714 | Phase II | Cetuximab + Durvalumab | Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03708224 | Phase II | Atezolizumab + Emactuzumab Atezolizumab | Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03719690 | Phase II | Tipifarnib | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) | Completed | USA | NOR | NLD | ITA | GRC | GBR | ESP | DNK | DEU | BEL | AUT | AUS | 4 |
NCT03723967 | Phase II | Carboplatin + Durvalumab + Paclitaxel | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE) | Completed | FRA | 0 |
NCT03735290 | Phase Ib/II | Pembrolizumab Intuvax + Pembrolizumab | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) | Terminated | USA | 0 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03740100 | Phase II | PQR309 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC) | Terminated | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03758781 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Completed | USA | 0 |
NCT03769311 | Phase II | Cetuximab | Cetuximab in Head and Neck Cancer Patients | Completed | USA | 0 |
NCT03769506 | Phase III | Methotrexate Cetuximab ASP-1929 Docetaxel Paclitaxel | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | Recruiting | USA | 3 |
NCT03771820 | Phase II | Pembrolizumab NC-6004 + Pembrolizumab | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | Unknown status | POL | HUN | HRV | CZE | 4 |
NCT03789097 | Phase Ib/II | CDX-301 + Pembrolizumab + Poly ICLC | Vaccination With Flt3L, Radiation, and Poly-ICLC | Recruiting | USA | 0 |
NCT03795610 | Phase II | Eganelisib | Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03799744 | Phase I | Durvalumab + VCN-01 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | Unknown status | ESP | 0 |
NCT03803774 | Phase I | Birinapant | Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03813836 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY) | Active, not recruiting | GBR | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03823131 | Phase II | Epacadostat + Pembrolizumab + Tavokinogene telseplasmid | Tavokinogene Telseplasmid With Electroporation, Pembrolizumab, and Epacadostat in Treating Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck | Terminated | USA | 0 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
NCT03844763 | Phase Ib/II | Avelumab + Cyclophosphamide | Targeting the Tumor Microenvironment in R/M SCCHN (CONFRONT) | Unknown status | ITA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03854032 | Phase II | Nivolumab Linrodostat + Nivolumab | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | Terminated | USA | 0 |
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Terminated | USA | NLD | FRA | ESP | DEU | BEL | 0 |
NCT03878979 | Phase II | Nivolumab | Preoperative Immune Checkpoint Inhibitor for Patients With Recurrent or Metastatic SCCHN Undergoing Surgical Salvage | Completed | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03916627 | Phase II | Cemiplimab | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC | Recruiting | USA | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03937141 | Phase II | MIW815 + Pembrolizumab | Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer | Terminated | USA | 0 |
NCT03938337 | Phase II | Abemaciclib + Pembrolizumab | Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer | Terminated | USA | 0 |
NCT03944915 | Phase II | Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel | De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) | Recruiting | USA | 0 |
NCT03946358 | Phase II | Atezolizumab + UCPVax | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL) | Active, not recruiting | FRA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | AUS | 2 |
NCT03973333 | Phase Ib/II | Atezolizumab + IMC-C103C IMC-C103C | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Withdrawn | USA | GBR | ESP | 0 |
NCT03978689 | Phase I | CUE-101 + Pembrolizumab CUE-101 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03991741 | Phase I | Aldesleukin | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | Recruiting | USA | 0 |
NCT03993353 | Phase II | Pembrolizumab + Tadalafil | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | Recruiting | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04000529 | Phase I | Spartalizumab + TNO155 Ribociclib + TNO155 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Terminated | USA | ESP | DEU | BEL | AUS | 4 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Terminated | USA | ITA | GBR | AUS | 2 |
NCT04034225 | Phase Ib/II | PAN-301-1 + Pembrolizumab | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | Terminated | USA | 0 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Completed | USA | NZL | AUS | 3 |
NCT04052204 | Phase II | Avelumab + NKTR-214 Avelumab + NKTR-214 + Talazoparib Avelumab + Enzalutamide + NKTR-214 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | Terminated | USA | POL | ESP | BEL | 0 |
NCT04058145 | Phase II | Pembrolizumab + Plerixafor | AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma | Withdrawn | USA | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04069026 | Phase I | BAY2416964 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | Completed | USA | GBR | ESP | DEU | CAN | 0 |
NCT04080804 | Phase II | Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | Recruiting | USA | 0 |
NCT04091867 | Phase I | Cetuximab + sEphB4-HSA | sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories | Completed | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04107103 | Phase II | Nivolumab + Pemetrexed Disodium | Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus) | Completed | CAN | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
NCT04128696 | Phase III | Pembrolizumab GSK3359609 + Pembrolizumab | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) | Terminated | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | AUS | ARG | 7 |
NCT04135352 | Phase I | Pembrolizumab + V938 | A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) | Terminated | USA | ISR | CAN | 0 |
NCT04144517 | Phase II | ALKS 4230 + Pembrolizumab | A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer | Completed | USA | 0 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04150900 | Phase II | Bavituximab + Pembrolizumab | 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | 0 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | SVK | AUS | 2 |
NCT04169074 | Phase II | Abemaciclib Abemaciclib + Nivolumab | Modulation of the Tumor Microenvironment by Abemaciclib in Operable HPV-Negative Head and Neck Cancer (HNC) | Recruiting | USA | 0 |
NCT04180215 | Phase Ib/II | HB-201 + HB-202 HB-201 + Nivolumab HB-201 HB-201 + HB-202 + Nivolumab | A Study of TheraT Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers | Recruiting | USA | NLD | ESP | 0 |
NCT04188951 | Phase I | Pembrolizumab | HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer | Recruiting | USA | 0 |
NCT04193293 | Phase Ib/II | Duvelisib + Pembrolizumab | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Terminated | USA | 0 |
NCT04196283 | Phase I | ABBV-368 + IMO-2125 ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-368 + Budigalimab + IMO-2125 + Nab-paclitaxel | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Completed | USA | NLD | ISR | FRA | ESP | DEU | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04220775 | Phase Ib/II | Bintrafusp alfa | M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer | Terminated | USA | 0 |
NCT04220866 | Phase II | Pembrolizumab + Ulevostinag Pembrolizumab | Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) | Completed | USA | NOR | ISR | GBR | FRA | ESP | BRA | AUT | AUS | 1 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04247282 | Phase Ib/II | Bintrafusp alfa Bintrafusp alfa + ETBX-011 + ETBX-051 + ETBX-061 Bintrafusp alfa + ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept | Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection | Completed | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04262388 | Phase II | Durvalumab + Oleclumab | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) | Withdrawn | CAN | 0 |
NCT04266730 | Phase I | PANDA-VAC + Pembrolizumab + Poly ICLC | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) | Not yet recruiting | USA | 0 |
NCT04272333 | Phase I | Motolimod + Nivolumab | Intratumoral Microdosing of Motolimod in HNSCC | Terminated | USA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04282109 | Phase II | Nivolumab + Paclitaxel Cetuximab + Paclitaxel | Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX) | Completed | ESP | 0 |
NCT04290546 | Phase I | CIML-NK cells + Ipilimumab + Nogapendekin alfa inbakicept CIML-NK cells + Nogapendekin alfa inbakicept | CIML NK Cell in Head & Neck Cancer | Active, not recruiting | USA | 0 |
NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Active, not recruiting | USA | 0 |
NCT04305795 | Phase Ib/II | ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04313504 | Phase II | Dostarlimab-gxly + Niraparib | Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
NCT04326257 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | Active, not recruiting | USA | 0 |
NCT04338399 | Phase III | Buparlisib + Paclitaxel Paclitaxel | The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN) | Active, not recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 5 |
NCT04340258 | Phase Ib/II | Pembrolizumab | Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC | Active, not recruiting | USA | 0 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT04349267 | Phase Ib/II | BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Terminated | USA | CAN | 1 |
NCT04357873 | Phase II | Pembrolizumab + Vorinostat | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) | Active, not recruiting | FRA | 0 |
NCT04369937 | Phase II | Cisplatin + ISA101b + Pembrolizumab | HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04375384 | Phase II | Cetuximab | Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy | Recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04414540 | Phase II | Metformin + Pembrolizumab | Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients | Active, not recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
NCT04428151 | Phase II | Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | Active, not recruiting | USA | ROU | NOR | ISR | GBR | FRA | ESP | DNK | CAN | BRA | AUS | 4 |
NCT04428333 | Phase III | Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | SWE | ROU | POL | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 3 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT04452214 | Phase I | Nidanilimab + Pembrolizumab | A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors | Completed | USA | 0 |
NCT04453046 | Phase I | Pembrolizumab | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Terminated | USA | 0 |
NCT04454489 | Phase II | Pembrolizumab | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | Active, not recruiting | USA | 0 |
NCT04459715 | Phase III | Cisplatin + Xevinapant Cisplatin | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | Terminated | USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT04465487 | Phase I | Cemiplimab + REGN6569 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | Recruiting | USA | ESP | 0 |
NCT04470024 | Phase I | DPV-001 + INCAGN01876 + Retifanlimab DPV-001 + Retifanlimab | Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC | Recruiting | USA | 0 |
NCT04471415 | Phase Ib/II | DRP-104 Atezolizumab + DRP-104 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Terminated | USA | ESP | DEU | 2 |
NCT04474470 | Phase Ib/II | Cetuximab + NT219 NT219 | A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | Completed | USA | ISR | 0 |
NCT04477759 | Phase I | Atezolizumab | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) | Active, not recruiting | USA | 0 |
NCT04489888 | FDA approved | Carboplatin + Paclitaxel + Pembrolizumab | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | Completed | USA | CAN | BRA | AUS | ARG | 0 |
NCT04502888 | Phase I | SL-172154 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Terminated | USA | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
NCT04533750 | Phase I | Peposertib | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin | Recruiting | USA | 0 |
NCT04534205 | Phase II | BNT113 + Pembrolizumab Pembrolizumab | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) | Recruiting | USA | TUR | SWE | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT04555837 | Phase Ib/II | Alisertib + Pembrolizumab | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | Active, not recruiting | USA | 0 |
NCT04574583 | Phase Ib/II | Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Completed | USA | 0 |
NCT04576091 | Phase I | Elimusertib + Pembrolizumab | Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT04590963 | Phase III | Cetuximab Cetuximab + Monalizumab | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1) | Active, not recruiting | USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 6 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04601402 | Phase I | Avelumab + GEN-001 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | Completed | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04616196 | Phase Ib/II | Cetuximab + NKTR-255 | A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Completed | USA | 0 |
NCT04624113 | Phase Ib/II | Pembrolizumab + Tazemetostat | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Terminated | USA | 0 |
NCT04633278 | Phase II | Pembrolizumab + Vidutolimod | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT04634825 | Phase II | MGA271 + Retifanlimab MGA271 + MGD013 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Terminated | USA | POL | HUN | ESP | BGR | AUS | 1 |
NCT04643379 | Phase II | Carboplatin + Olaparib + Pembrolizumab Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04665843 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) | Active, not recruiting | USA | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | CZE | 3 |
NCT04671667 | Phase II | Cisplatin Pembrolizumab Carboplatin | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04675294 | Phase II | Evorpacept + Pembrolizumab Pembrolizumab | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Active, not recruiting | USA | NLD | GBR | ESP | CAN | BEL | AUS | 2 |
NCT04675333 | Phase II | Carboplatin + Evorpacept + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Evorpacept + Fluorouracil + Pembrolizumab | ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUS | 2 |
NCT04681469 | Phase II | Dostarlimab-gxly + Niraparib | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (PRIME) | Recruiting | ITA | 0 |
NCT04685499 | Phase II | OBP-301 + Pembrolizumab | Phase 2 Study of OBP-301 (Telomelysin) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease | Terminated | USA | 0 |
NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Completed | USA | CAN | 0 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04713046 | Phase Ib/II | Allogeneic HPV-specific T cells | Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers | Recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04722523 | Phase I | Cemiplimab + Cetuximab + Cisplatin + Docetaxel Carboplatin + Cemiplimab + Cetuximab + Docetaxel | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Recruiting | USA | 0 |
NCT04747054 | Phase III | Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) | Recruiting | FRA | 0 |
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |
NCT04754321 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer | Recruiting | USA | 0 |
NCT04762225 | Phase I | RPTR-168 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma | Terminated | USA | 0 |
NCT04777994 | Phase I | ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Recruiting | USA | ISR | FRA | ESP | 2 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04795713 | Phase I | MT-6402 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Terminated | USA | 0 |
NCT04811027 | Phase II | Eftilagimod alpha + Pembrolizumab Pembrolizumab | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) | Active, not recruiting | USA | ROU | GBR | ESP | DNK | DEU | BEL | AUS | 1 |
NCT04815720 | Phase Ib/II | Pembrolizumab + Pepinemab | Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84) | Recruiting | USA | 0 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04830592 | Phase I | NG-641 NG-641 + Pembrolizumab | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT) | Active, not recruiting | GBR | 0 |
NCT04831320 | Phase II | Nab-paclitaxel + Nivolumab | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | Active, not recruiting | USA | 0 |
NCT04834349 | Phase II | NBTXR3 + Pembrolizumab | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer | Withdrawn | 0 | |
NCT04844073 | Phase Ib/II | MVC-101 | A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer | Recruiting | USA | GBR | AUS | 1 |
NCT04847466 | Phase II | Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | Recruiting | USA | 0 |
NCT04848116 | Phase II | Cabiralizumab + Nivolumab BMS-986253 + Nivolumab Nivolumab | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2) | Recruiting | USA | 0 |
NCT04854499 | Phase II | Carboplatin + Fluorouracil + Pembrolizumab Docetaxel + Hu5F9-G4 Cisplatin + Fluorouracil + Pembrolizumab Hu5F9-G4 + Pembrolizumab Carboplatin + Fluorouracil + Hu5F9-G4 + Pembrolizumab Cisplatin + Fluorouracil + Hu5F9-G4 + Pembrolizumab | Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma | Terminated | USA | POL | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT04862455 | Phase II | NBTXR3 + Pembrolizumab | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer | Recruiting | USA | 0 |
NCT04862650 | Phase II | Carboplatin + Cemiplimab + Paclitaxel | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Suspended | USA | 0 |
NCT04879849 | Phase I | Pembrolizumab + TAK-676 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | Completed | USA | 0 |
NCT04892875 | Phase I | Cisplatin + Zimberelimab Cisplatin Cisplatin + Etrumadenant + Zimberelimab | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) | Withdrawn | 0 | |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04936841 | Phase II | NKTR-214 + Pembrolizumab | NKTR With Radiation for Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
NCT04938609 | Phase II | Pembrolizumab | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | Recruiting | USA | 0 |
NCT04939480 | Phase II | Atezolizumab | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (PIONEER) | Completed | DEU | 0 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04966481 | Phase III | Cetuximab + Palbociclib Cetuximab | Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor | Recruiting | USA | 0 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT04969861 | Phase II | NKTR-214 + Pembrolizumab Pembrolizumab | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Terminated | USA | ITA | GRC | AUT | 0 |
NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Withdrawn | USA | 0 |
NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUT | 0 |
NCT04997902 | Phase Ib/II | Alpelisib + Tipifarnib | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Recruiting | USA | 0 |
NCT04999202 | Phase I | BAY2416964 + Pembrolizumab BAY2416964 | A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults | Active, not recruiting | USA | ITA | GBR | 1 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
NCT05005403 | Phase I | ABBV-514 + Budigalimab ABBV-514 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab | Recruiting | USA | ISR | 3 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05047094 | Pembrolizumab | A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | Recruiting | ISR | 0 | |
NCT05053737 | Phase Ib/II | Atezolizumab | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | Suspended | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05057247 | Phase II | Docetaxel + Duvelisib | Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
NCT05061420 | Phase II | Cetuximab + Pembrolizumab + THOR-707 Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | CAN | ARG | 3 |
NCT05063552 | Phase II | Bevacizumab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Bevacizumab + Carboplatin + Docetaxel Cetuximab + Cisplatin + Docetaxel Atezolizumab + Bevacizumab | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | Recruiting | USA | 0 |
NCT05068102 | Phase I | BI 770371 + Ezabenlimab Effi-DEM + Ezabenlimab | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | Recruiting | NLD | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05075122 | Phase II | Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab | Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS) | Recruiting | DEU | 0 |
NCT05077709 | Phase II | IO102-IO103 + Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Active, not recruiting | USA | GBR | ESP | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05094336 | Phase Ib/II | AMG193 AMG193 + Docetaxel | A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (MTAP) | Recruiting | USA | GBR | FRA | DEU | CHE | CAN | BEL | AUT | AUS | 5 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Terminated | USA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05102214 | Phase Ib/II | HLX301 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05110781 | Phase II | Atezolizumab | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | Terminated | USA | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Terminated | USA | 0 |
NCT05132803 | Phase I | TA-CIN | TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers | Withdrawn | USA | 0 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05172245 | Phase I | Cisplatin + Ipatasertib | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Recruiting | USA | CAN | 0 |
NCT05172258 | Phase II | Ipatasertib + Pembrolizumab Pembrolizumab | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | Recruiting | USA | 0 |
NCT05208762 | Phase I | SGN-PDL1V | A Study of SGN-PDL1V in Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT05216432 | Phase I | RLY-2608 Fulvestrant + RLY-2608 | First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | Recruiting | USA | ITA | FRA | ESP | AUS | 0 |
NCT05220748 | Phase I | Pembrolizumab + RM-1995 RM-1995 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | Withdrawn | 0 | |
NCT05222932 | Phase I | Avelumab + TILT-123 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL) | Recruiting | USA | FIN | 0 |
NCT05229601 | Phase I | HFB301001 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | ESP | 0 |
NCT05229614 | Phase II | Pembrolizumab | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) | Recruiting | ITA | DEU | 0 |
NCT05233436 | Phase I | PF-07265028 PF-06801591 + PF-07265028 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | Terminated | USA | 1 |
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05249426 | Phase I | Cetuximab + Effi-DEM + Ezabenlimab BI 836880 + Effi-DEM + Ezabenlimab Effi-DEM + Ezabenlimab | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | Active, not recruiting | USA | ROU | POL | GBR | FRA | ESP | 5 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05271604 | Phase II | BA3021 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05280314 | Phase II | IO102-IO103 + Pembrolizumab | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors | Recruiting | USA | FRA | ESP | DNK | DEU | AUS | 0 |
NCT05283226 | Phase II | NRC-2694-A + Paclitaxel | Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | Recruiting | USA | 1 |
NCT05287113 | Phase II | INCAGN02385 + Retifanlimab Retifanlimab INCAGN02385 + INCAGN02390 + Retifanlimab | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting | USA | POL | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BEL | 4 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT05312710 | Phase II | APG-157 | Safety and Efficacy of APG-157 in Head and Neck Cancer | Recruiting | USA | 0 |
NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Active, not recruiting | NLD | ITA | GBR | BEL | 0 |
NCT05323656 | Phase II | Pembrolizumab Pembrolizumab + Setanaxib | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05354323 | Phase I | NECVAX-NEO1 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | Recruiting | LTU | 0 |
NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
NCT05376553 | Phase I | Cemiplimab + Cisplatin + Docetaxel | Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
NCT05383170 | Phase Ib/II | Cypep-1 + Pembrolizumab | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst) | Completed | USA | NLD | ITA | FRA | ESP | 0 |
NCT05393635 | Phase I | ITIL-168 + Pembrolizumab | ITIL-168 in Advanced Solid Tumors (DELTA-2) | Withdrawn | 0 | |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05435339 | Phase Ib/II | GEN1053 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | Terminated | USA | ESP | 0 |
NCT05459129 | Phase Ib/II | Atezolizumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | Completed | USA | ISR | FRA | AUS | 1 |
NCT05462873 | Phase I | QEQ278 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |
NCT05472506 | Phase I | KYN-175 + Nivolumab | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | Withdrawn | USA | 0 |
NCT05483400 | Phase II | Atezolizumab + Tiragolumab | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) | Recruiting | NLD | 0 |
NCT05487235 | Phase I | Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | POL | NZL | ESP | CAN | BRA | AUS | ARG | 2 |
NCT05526924 | Phase I | Fluorouracil + Hydroxyurea + Pamiparib + Tislelizumab | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer | Recruiting | USA | 0 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05537740 | Phase I | BAY 3375968 + Pembrolizumab BAY 3375968 | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | 2 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Recruiting | USA | CAN | 0 |
NCT05577182 | Phase I | INCA32459 | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | Active, not recruiting | USA | ITA | ESP | BEL | 0 |
NCT05584709 | Phase I | STI-6129 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Recruiting | USA | AUS | 0 |
NCT05608369 | Phase II | Cisplatin Cisplatin + Vorinostat | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV) | Not yet recruiting | USA | 0 |
NCT05608876 | Phase II | Tigilanol tiglate | A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer | Recruiting | GBR | AUS | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05635643 | Phase Ib/II | SRF114 | Study of SRF114 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05647122 | Phase I | AZD9592 AZD9592 + Osimertinib | First in Human Study of AZD9592 in Solid Tumors (EGRET) | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 5 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05674526 | Phase I | Cetuximab + WU-NK-101 | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | Recruiting | USA | 0 |
NCT05678348 | Phase I | Pyrimethamine | Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Recruiting | USA | ESP | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05724602 | Phase II | Xevinapant | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA) | Suspended | SVN | NOR | NLD | ITA | IRL | GBR | FRA | ESP | DEU | BEL | 0 |
NCT05726370 | Phase II | Carboplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | Recruiting | USA | 0 |
NCT05743270 | Phase II | Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Withdrawn | USA | POL | GRC | GBR | FRA | ESP | DEU | CZE | 0 |
NCT05768139 | Phase Ib/II | Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05814666 | Phase II | Pembrolizumab Danvatirsen + Pembrolizumab | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN) | Recruiting | USA | GBR | 1 |
NCT05816785 | Phase I | Cetuximab + Imatinib | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer | Recruiting | USA | 0 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT05838729 | Phase Ib/II | Nivolumab + RiMO-301 Pembrolizumab + RiMO-301 | Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer | Recruiting | USA | 0 |
NCT05845307 | Phase I | C188-9 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | Not yet recruiting | USA | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT05877430 | Phase Ib/II | CJRB-101 + Pembrolizumab | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | Recruiting | USA | 1 |
NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05913388 | Phase II | Pembrolizumab GB1211 + Pembrolizumab | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05930938 | Phase III | Cetuximab Cetuximab + Xevinapant | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01) | Suspended | FRA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05977907 | Phase II | IO102-IO103 + Pembrolizumab | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO) | Recruiting | USA | 0 |
NCT05980000 | Phase II | Pembrolizumab + Ramucirumab Pembrolizumab | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2) | Recruiting | USA | 0 |
NCT05980598 | Phase II | Pembrolizumab + TransCon TLR7/8 Agonist TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist Pembrolizumab | TransCon (TC) TLR7/8 Agonist, TC IL-2 beta/gamma, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201) | Recruiting | USA | POL | ITA | HUN | ESP | DEU | 2 |
NCT05983133 | Phase I | SGN-EGFRd2 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT06003231 | Phase II | Disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06016920 | Phase Ib/II | Pembrolizumab + VB10.16 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | Recruiting | POL | NOR | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT06026410 | Phase I | Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT06035744 | Phase I | CLN-617 + Pembrolizumab | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06036121 | Phase I | ADRX-0706 | A Study of ADRX-0706 in Select Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06052839 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC | Recruiting | USA | 0 |
NCT06054477 | Phase Ib/II | ALE.C04 + Pembrolizumab ALE.C04 Pembrolizumab | Study of ALE.C04 in Patients With Head and Neck Cancer | Recruiting | USA | ITA | FRA | ESP | CHE | CAN | 2 |
NCT06056310 | Phase I | Cisplatin + Xevinapant Xevinapant | Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | Terminated | USA | ISR | ESP | BEL | 2 |
NCT06062420 | Phase II | Dostarlimab-gxly Dostarlimab-gxly + EOS-448 + GSK6097608 Dostarlimab-gxly + GSK6097608 Dostarlimab-gxly + EOS-448 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 | Recruiting | USA | TUR | ROU | POL | NOR | ITA | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CAN | BRA | ARG | 4 |
NCT06064877 | Phase III | Cetuximab + Ficlatuzumab Cetuximab | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) | Recruiting | USA | GBR | CAN | AUS | 2 |
NCT06082167 | Phase II | Pembrolizumab + XL092 Pembrolizumab | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305) | Recruiting | USA | SVK | ROU | ITA | FRA | ESP | CZE | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | ISR | ESP | AUS | 4 |
NCT06096038 | Phase Ib/II | iC9.CAR-CSPG4 T cells Cyclophosphamide + Fludarabine | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Recruiting | USA | 0 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06110195 | Phase I | Carboplatin + Paclitaxel + Xevinapant | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT06145412 | Phase II | Cisplatin + Xevinapant | A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06159621 | Phase I | LVGN3616 LVGN3616 + LVGN7409 | CD40 Agonist and PD-1 Inhibitor in HNSCC | Recruiting | USA | 0 |
NCT06161545 | Phase II | Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | Not yet recruiting | USA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06182579 | Phase I | RiMO-401 | Phase I Study of RiMO-401 With Radiation in Advanced Tumors | Recruiting | USA | 0 |
NCT06211335 | Phase I | Losartan + Pembrolizumab | Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT06236425 | Phase I | Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | Recruiting | USA | 0 |
NCT06237881 | Phase Ib/II | Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06239220 | Phase II | Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells | PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06273852 | Phase I | PBA-0405 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06295731 | Phase II | INBRX-106 + Pembrolizumab Pembrolizumab | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS>=20 HNSCC (HexAgon-HN) | Recruiting | USA | 0 |
NCT06305247 | Phase Ib/II | IPN01194 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Recruiting | USA | FRA | ESP | 0 |
NCT06308913 | Phase I | INCB081776 + Pembrolizumab | Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06332092 | Phase II | Cetuximab + FID-007 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | USA | 0 |
NCT06332755 | Phase I | LB-LR1109 | Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) | Recruiting | USA | 0 |
NCT06357858 | Phase I | Decitabine and Cedazuridine + Nivolumab | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | Withdrawn | USA | 0 |
NCT06366451 | Phase I | AZD2936 Pembrolizumab AZD7789 MEDI5752 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | Recruiting | USA | 0 |
NCT06373380 | Phase II | HB-201 + HB-202 | A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) | Recruiting | USA | 0 |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06385080 | Phase Ib/II | Amivantamab-vmjw Amivantamab-vmjw + Pembrolizumab Amivantamab-vmjw + Paclitaxel | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4) | Recruiting | USA | GBR | 3 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06470763 | Phase Ib/II | ANV600 ANV600 + Pembrolizumab | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06496568 | Phase I | Atezolizumab + Inavolisib Inavolisib | A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers | Recruiting | USA | CAN | 1 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06525220 | Phase III | Pembrolizumab MCLA-158 + Pembrolizumab | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer | Recruiting | USA | ISR | AUS | ARG | 3 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06544655 | Phase I | BMS-986484 + Nivolumab BMS-986484 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT06557889 | Phase II | Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (REDUCE) | Recruiting | FRA | 0 |
NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Recruiting | USA | 0 |
NCT06597565 | Phase II | Gemcitabine + Prexasertib | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Recruiting | USA | 0 |
NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Not yet recruiting | AUS | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06636734 | Phase II | Lovastatin + Pembrolizumab | Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | Not yet recruiting | USA | 0 |
NCT06639191 | Phase I | 177Lu-AKIR001 | [177Lu]Lu-AKIR001 First-in-human Study (AKIR001) | Not yet recruiting | SWE | 0 |
NCT06648096 | Phase Ib/II | Afatinib | Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (AFAN) | Not yet recruiting | ESP | DEU | 0 |